C4 Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
490 Arsenal Way Ste 120, Watertown, Mass...Phone Number
(617) 231-0700Website
www.c4therapeutics.comRevenue
$35 MillionStock Symbol
CCCCIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About C4 Therapeutics
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines through targeted protein degradation. The company uses its scientific platform to design small-molecule therapies that harness the body’s natural protein recycling system to identify and eliminate disease-causing proteins. Its research and development efforts focus primarily on oncology and other difficult-to-treat diseases. C4 Therapeutics combines expertise in drug discovery, biology, chemistry, and clinical development to advance potential therapies that may address challenging disease targets, overcome drug resistance, and improve patient outcomes through a new approach to precision medicine.Explore more
C4 Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is C4 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once C4 Therapeutics has new funding data
Earning: See what the market has to say on C4 Therapeutics recently announced quarterly report
Check if C4 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if C4 Therapeutics had a recent Job posting/layoffs
C4 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when C4 Therapeutics launches new products
Check out if C4 Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at C4 Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to C4 Therapeutics
Compare insights from companies similar to C4 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
C4 Therapeutics
$35M
51-200
Public
$425M
2015
Kendra AdamsChief Financial Officer & Head Corporate Affairs & Principal Accounting Officer
Company Profile Activity
Activity Insights
C4 Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
C4 Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about C4 Therapeutics.
C4 Therapeutics financials insights
Gather financial insights about C4 Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$73M
2020
Multiple Rounds
$352M
C4 Therapeutics Tech Stack
A closer look at the technologies used by C4 Therapeutics
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance, Tax
Open Position
Project
C4 Therapeutics has reported efficacy data from the phase I trial of cemsidomide, with an overall response rate of 53% at the recommended phase dose of 100 micrograms (19 patients), including two stringent complete responses with MRD negativity, and an overall response rate of 36% across all dose levels in combination with dexamethasone.
Medical Research, Clinical Operations
Project
C4 Therapeutics has initiated enrollment in the phase II MOMENTUM trial of cemsidomide in the late-line multiple myeloma setting, with enrollment on track to complete by the end of Q1 2027 and initial overall response rate data expected in the second half of 2027, positioning the trial for potential accelerated approval.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals, Clinical Operations
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding C4 Therapeutics
Sign Up For FreeTo access detailed company insights
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines through targeted protein degradation. The company uses its scientific platform to design small-molecule therapies that harness the body’s natural protein recycling system to identify and eliminate disease-causing proteins. Its research and devel... Read More
